187.07
+6.02(+3.33%)
Currency In USD
| Previous Close | 181.05 |
| Open | 181.84 |
| Day High | 187.31 |
| Day Low | 181.22 |
| 52-Week High | 187.32 |
| 52-Week Low | 55.92 |
| Volume | 688,217 |
| Average Volume | 462,798 |
| Market Cap | 6.01B |
| PE | -64.29 |
| EPS | -2.91 |
| Moving Average 50 Days | 153.2 |
| Moving Average 200 Days | 121.37 |
| Change | 6.02 |
If you invested $1000 in iRhythm Technologies, Inc. (IRTC) since IPO date, it would be worth $7,181.19 as of September 09, 2025 at a share price of $187.07. Whereas If you bought $1000 worth of iRhythm Technologies, Inc. (IRTC) shares 5 years ago, it would be worth $866.67 as of September 09, 2025 at a share price of $187.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service
GlobeNewswire Inc.
Aug 29, 2025 11:00 AM GMT
Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhy
AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority
GlobeNewswire Inc.
Aug 18, 2025 12:05 PM GMT
In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Fin
iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions
GlobeNewswire Inc.
Jul 31, 2025 8:10 PM GMT
Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed